Dean W. Hum
Lons, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
Journal: JHEP reports : innovation in hepatology
Published: August 29, 2023
NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
Journal: Journal of hepatology
Published: March 31, 2023
NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
Journal: Journal of hepatology
Published: December 14, 2022
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Journal: The lancet. Gastroenterology & hepatology
Published: February 25, 2020
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Journal: Gastroenterology
Published: October 19, 2015
The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
Journal: Diabetes & vascular disease research
Published: September 13, 2014
The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1).
Journal: Journal of biomolecular screening
Published: July 31, 2013
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Journal: Hepatology (Baltimore, Md.)
Published: August 23, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026